Micreos
A Netherlands-based biotechnology company developing phage- and endolysin-based solutions for targeted bacterial control.
Last updated August 24, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Micreos BV is a Netherlands-based biotechnology company focused on bacteriophage and endolysin technologies. Its work addresses the selective control of specific bacteria in healthcare, skincare, and food processing rather than relying solely on broad-spectrum chemical or antibiotic approaches. The company developed Staphefekt, an endolysin designed to selectively destroy Staphylococcus aureus, including strains associated with inflammatory skin conditions. Staphefekt is used as an active ingredient in the company's Gladskin skincare brand, which is positioned for people dealing with conditions such as acne, rosacea, and eczema-related inflammation, although the available reference material does not provide a complete product catalogue or detailed clinical claims for each formulation. Micreos also develops bacteriophage- and endolysin-based applications for food safety. Its Listex product is an antimicrobial processing aid intended to reduce or prevent Listeria contamination in food products such as meat, fish, and cheese. The reference material states that relevant uses of Listex have received approvals or authorizations from the United States Department of Agriculture, Health Canada, and Food Standards Australia New Zealand. The company has also developed Salmonelex, a product intended to help prevent cross-contamination and reduce undesirable Salmonella on food during processing. Salmonelex has been recognized by the United States Food and Drug Administration as a GRAS processing aid. Micreos's technology model is based on biological specificity. Bacteriophages are viruses that infect bacteria, while endolysins are enzymes produced during bacteriophage infection that can break down bacterial cell walls. By applying these mechanisms to selected pathogens, Micreos seeks to target bacteria while limiting effects on beneficial microorganisms and the broader food or skin environment. This approach gives the company a position at the intersection of biotechnology, antimicrobial development, food safety, and consumer healthcare. The available material identifies Micreos as an active developer of phage and endolysin products, but does not establish its founding year, founder, ownership structure, current leadership, revenue, public listing, or a complete account of its present commercial operations. Its documented portfolio nevertheless shows a diversified application strategy: Gladskin brings the technology into consumer skincare, while Listex and Salmonelex address industrial food-processing and contamination-control needs. The company therefore appears to operate as a specialized biotechnology enterprise whose commercial proposition is built around targeted bacterial management across multiple sectors.
History
Micreos BV is a biotechnology company from the Netherlands specializing in bacteriophage and endolysin technology. The available reference material does not document the company's founding date, founders, early financing, or initial research program, so its early corporate history cannot be reconstructed reliably here. The company's identifiable development path centers on translating bacteriophage biology into selective antimicrobial products. Rather than treating bacteria through broadly acting chemical disinfectants or conventional antibiotics, Micreos has developed technologies intended to recognize and destroy particular bacterial targets. Endolysins are enzymes associated with bacteriophage biology that can break down bacterial cell walls. Micreos applied this approach to Staphefekt, an endolysin directed at Staphylococcus aureus. Staphefekt became the basis for the company's Gladskin skincare brand. Gladskin uses the ingredient in products aimed at inflammatory skin concerns. The skincare application represents Micreos's consumer-facing activity and connects its underlying biotechnology with conditions in which Staphylococcus aureus may be relevant. The available material identifies Gladskin as the brand using Staphefekt but does not supply a detailed launch chronology, product-by-product history, or clinical development timeline. Micreos subsequently or additionally developed applications for food safety. Listex was created as an antimicrobial processing aid for controlling Listeria in foods, including meat, fish, and cheese. Its regulatory history includes approvals or authorizations for stated uses from the United States Department of Agriculture, Health Canada, and Food Standards Australia New Zealand. These regulatory milestones indicate that the company moved beyond laboratory development into regulated food-processing applications in several jurisdictions. The company's food-safety portfolio also includes Salmonelex, which is intended to help prevent cross-contamination and reduce undesirable Salmonella during food processing. The reference material states that the United States Food and Drug Administration recognized Salmonelex as a GRAS processing aid. This placed another Micreos technology within the regulatory framework used for ingredients and processing aids considered generally recognized as safe for specified uses. Taken together, Micreos's documented history is one of platform development across two principal commercial domains: targeted skincare and industrial food safety. The company has used endolysin technology for a consumer product associated with Staphylococcus aureus and phage-based or related antimicrobial technology for foodborne pathogens such as Listeria and Salmonella. Information about later corporate developments, ownership, leadership, financial performance, and current geographic scale is not established by the supplied sources.
Development of Staphefekt
[1]Micreos developed Staphefekt, an endolysin designed to selectively kill Staphylococcus aureus bacteria.
Launch of the Gladskin platform
[1]Staphefekt became an ingredient in Gladskin, Micreos's skincare brand for products targeting inflammatory skin conditions.
Regulatory clearances for Listex uses
[1]Listex, an antimicrobial processing aid for reducing Listeria in foods such as meat, fish, and cheese, received approvals or authorizations for relevant uses from USDA, Health Canada, and FSANZ.
FDA GRAS recognition for Salmonelex
[1]Salmonelex was recognized by the United States Food and Drug Administration as a GRAS processing aid for applications involving Salmonella control during food processing.
Products and positioning
Micreos positions itself around targeted biological control of harmful bacteria using bacteriophages and endolysins. Its applications span consumer skincare and professional food processing, emphasizing specificity against organisms such as Staphylococcus aureus, Listeria, and Salmonella.
Skincare brand
Gladskin
Gladskin is Micreos's consumer skincare brand built around Staphefekt, an endolysin intended to selectively target Staphylococcus aureus. The brand is associated with products aimed at inflammatory skin conditions. It represents the consumer-health application of Micreos's bacteriophage-derived technology, although the supplied sources do not provide a full formulation list, launch date, or detailed market history.
Endolysin
Staphefekt
Staphefekt is an endolysin developed by Micreos to selectively kill Staphylococcus aureus bacteria. It is used as an ingredient in Gladskin products and is the clearest example of the company's effort to apply phage-derived enzymes to targeted antimicrobial skincare. The available reference does not specify its development date, regulatory classification in every market, or complete clinical evidence base.
Food-processing antimicrobial
Listex
Listex is an antimicrobial processing aid developed to help prevent or reduce Listeria contamination in food products, including meat, fish, and cheese. Its documented regulatory footprint includes approvals or authorizations for relevant uses from the United States Department of Agriculture, Health Canada, and Food Standards Australia New Zealand. It is designed for use in food-processing environments rather than as a consumer retail product.
Food-processing antimicrobial
Salmonelex
Salmonelex is a Micreos product intended to help prevent cross-contamination and reduce undesirable Salmonella on food during processing. The supplied source states that the product has been recognized by the United States Food and Drug Administration as a GRAS processing aid. No launch year, formulation details, or complete list of commercial markets is provided.
Recent events
Micreos appoints Joost Goderie as CFO[2]
Reported:
Micreos announced that Joost Goderie was appointed to its management board as Chief Financial Officer.
Micreos appoints Matt Regan as pharmaceutical business CEO[3]
Reported:
Micreos recruited Matt Regan as CEO of its new Pharmaceutical business, which is to be based in Switzerland.
L’Oréal signs license agreement with Micreos for cosmetic development[4]
Reported:
L’Oréal signed a license agreement with Micreos, under which Micreos would give L’Oréal access to an endolysin of interest in the cosmetic field. L’Oréal aims to develop cosmetic solutions targeting the skin microbiome.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/micreos · Editorial policy · How profiles are compiled